Core Viewpoint - The approval of the innovative aortic branch reconstruction stent system by the National Medical Products Administration (NMPA) marks a significant advancement in medical technology, providing a standardized tool for clinicians to address complex aortic arch diseases [1] Company Summary - Xianjian Technology (01302) experienced a stock price increase of over 3% in early trading, with a current price of 1.66 HKD and a trading volume of 24.8849 million HKD [1] - The newly approved product is the world's first aortic-branch stent system specifically designed for chimney technique reconstruction, consisting of Longuette skirt stent and Ankura Pro aortic main stent system [1] Industry Summary - The innovative product addresses dual challenges of leakage and occlusion associated with chimney techniques, enhancing the clinical advantages of this method [1] - The system aims to improve efficiency and precision in treating aortic arch diseases, ultimately benefiting patients with better clinical outcomes [1]
港股异动 | 先健科技(01302)早盘涨超3% 主动脉分支重建系统(烟囱型)获批上市